17. Zemdri

achaogen
(Achaogen)

Active ingredient: plazomicin
Disease: complicated urinary tract infections
Peak sales estimate: $500 million
Approved: June 26
Company: Achaogen

The scoop: Even as experts have lamented a lack of biopharma R&D work in antibiotics, South San Francisco biotech Achaogen secured FDA approval for its high-powered antibiotic Zemdri in June. While the FDA approved the med in drug-resistant urinary tract infections, regulators also gave the drug a black-box warning and turned it down for treating bloodstream infections. The drug is "designed to retain its potent activity" when attacking difficult-to-treat infections resistant to multiple antibiotics, CEO Blake Wise said in a statement at the time of approval. Analysts have projected peak sales of $500 million. Zemdri’s approval follows a separate nod for The Medicines Company’s Vabomere last year, also to treat complicated UTIs. — Eric Sagonowsky

17. Zemdri
Read more on

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.